Brief: Ideaya Announces Idmc Recommendation Of Move-Forward Dose In Part 2A Of Registration-Enabling Trial Of Darovasertib And Crizotinib Combination
17/12/2024 11:14
Dec 17 (Reuters) - IDEAYA Biosciences Inc IDYA.O :
* IDEAYA ANNOUNCES IDMC RECOMMENDATION OF MOVE-FORWARD DOSE
IN
PART 2A OF REGISTRATION-ENABLING TRIAL OF DAROVASERTIB AND
CRIZOTINIB COMBINATION IN 1L HLA-A2-NEGATIVE METASTATIC UVEAL
MELANOMA
* IDEAYA BIOSCIENCES INC - TARGETS PHASE 3 STUDY FOR UVEAL
MELANOMA IN FIRST HALF OF 2025
Source text: ID:nPn5t6HLGa
Further company coverage: IDYA.O
Recent news on IDEAYA Biosciences
See all newsBrief: Ideaya Biosciences And Servier Announce Data From Three Clinical Trials At Esmo 2026 Supporting The Potential Of Darovasertib To Become A Foundational New Therapy For Patients Across The Treatment Journey Of Uveal Melanoma
Brief: Ideaya Biosciences Announces The Promotion Of Dr. Michael White To President, Research And Development
Brief: Ideaya Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Ideaya Biosciences Inc Reports Results For The Quarter Ended June 30: Earnings Summary
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj